Membro del Comitato di Clinical Study Protocol ML 18253 “ A multicenter randomized, controlled study comparing the efficacy and safty of 48 weeks of 40 kD branched pegylated interferon alfa2a (PEGASYS®; Ro 25-8310) versus 96 weeks PEGASYS®, alone or in combination with 100 mg lamivudine for 48 weeks in patients with HbeAg-negative chronic hepatitis B” Sponsor : Roche S.p.A / CRO : Quintiles S.p.A. EudraCT Number: 2004-002985-39(2006 Jan).
Membro del Comitato di Clinical Study Protocol ML 18253 “ A multicenter randomized, controlled study comparing the efficacy and safty of 48 weeks of 40 kD branched pegylated interferon alfa2a (PEGASYS®; Ro 25-8310) versus 96 weeks PEGASYS®, alone or in combination with 100 mg lamivudine for 48 weeks in patients with HbeAg-negative chronic hepatitis B” Sponsor : Roche S.p.A / CRO : Quintiles S.p.A. EudraCT Number: 2004-002985-39
2006
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
